Reuters: Regulatory News: Another Supernus epilepsy drug gets FDA nod

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Another Supernus epilepsy drug gets FDA nod Oct 22nd 2012, 12:17 Mon Oct 22, 2012 8:17am EDT Oct 22 (Reuters) - Supernus Pharmaceuticals Inc's experimental epilepsy drug Oxtellar XR won marketing approval from the U.S. Food and Drug Administration, the second drug approval for the company since it went public in May. Oxtellar XR's final marketing approval follows the tentative approval given in late-June to Supernus's Trokendi XR -- a generic epilepsy treatment. The company plans to launch Oxtellar in the first quarter of 2013. Rockville, Maryland-based Supernus is developing several other drugs for epilepsy, depression and attention deficit hyperactivity disorder. Supernus's shares closed at $12.97 on Friday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions